Arcus Biosciences (RCUS) Stock Forecast & Price Target

Arcus Biosciences is viewed positively because casdatifan is showing a differentiated profile across ccRCC, with 2L cas+cabo delivering 44% ORR, 14.5-month mPFS, and 84%/77% 12-/18-month OS, while remaining effective in prior-TKI patients and appearing commercially advantaged through cabozantinib familiarity. Its 1L cas+zim data also support a broader franchise, with 50% cORR, only 6.7% primary progression, and 86%/69% 6-/12-month PFS, suggesting meaningful potential to improve early disease control versus IO-only approaches. In late-line disease, pooled cas monotherapy produced 35 months mOS in 121 patients and 36% cORR, reinforcing the case that cas may offer durable HIF-2α inhibition across multiple lines and support several registrational paths.

Arcus Biosciences is viewed negatively because its investment case is heavily dependent on pipeline execution, and the source material highlights the risk of clinical and regulatory failure for AB154 as well as the possibility that domvanalimab may not prove efficacious or could face safety issues that halt development. The company also faces meaningful commercialization uncertainty, since it may be unable to achieve sales estimates and could encounter competitive pressure from current and future therapies. As a late clinical-stage biopharmaceutical company with a single operating segment focused on developing and commercializing differentiated therapies, its outlook remains fragile because setbacks in one or more lead assets could materially impair future value creation.